This article reviews the evolving role of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in managing oligometastatic prostate cancer (OMPC).
PSMA PET has shown superior diagnostic utility compared to traditional imaging methods, improving the detection of early metastatic prostate cancer. The review highlights PSMA PET’s effectiveness in guiding metastasis-directed therapy (MDT), such as salvage surgery or radiotherapy, potentially delaying systemic therapy.
The article emphasizes the need for more extensive studies to solidify PSMA PET’s role in this context.
